Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  West Pharmaceutical Services Inc.    WST

Delayed Quote. Delayed  - 04/29 07:35:23 pm
70.89 USD   -1.91%
04/28 WEST PHARMACEUT : tops Street 1Q forecasts
04/28 WEST PHARMACEUT : Announces First Quarter 2016 Results
04/26 WEST PHARMACEUT : Gw&k Investment Management buys $85,409,482 stake ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201320142015201620172018
Sales1 3681 4211 4001 5001 6271 750
Operating income (EBITDA)248273280328379426
Operating profit (EBIT)162183190228272315
Pre-Tax Profit (EBT)------
Net income11212795,6161195236
P/E ratio31,230,446,334,827,723,3
EPS ( $ )1,571,751,302,082,613,10
Dividend per Share ( $ )0,390,410,460,490,530,58
Yield0,79%0,77%0,76%0,68%0,73%0,80%
Reference price ( $ )49.0653.2460.2272.2772.2772.27
Announcement Date02/20/2014
12:00pm
02/19/2015
12:00pm
02/18/2016
12:00pm
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201320142015201620172018
Debt---23,013,028,0
Finance------
Operating income (EBITDA)248273280328379426
Leverage
(Debt/EBITDA)
---0,07x0,03x0,07x
Capital Expenditure--132162158155
Book Value Per Share (BVPS)--14,2 $15,2 $16,9 $19,3 $
Cash Flow per Share3,09 $2,51 $2,88 $3,18 $3,85 $4,42 $
Announcement Date02/20/2014
12:00pm
02/19/2015
12:00pm
02/18/2016
12:00pm
---
Balance Sheet Analysis
Assessed data source :
© 2016 Thomson Reuters
Advertisement
Financial Ratios

Size 2016e 2017e
Capitalization 5 255 M$ -
Entreprise Value (EV) 5 278 M$ 5 268 M$
Valuation 2016e 2017e
P/E ratio (Price / EPS) 34,8x 27,7x
Capitalization / Revenue 3,50x 3,23x
EV / Revenue 3,52x 3,24x
EV / EBITDA 16,1x 13,9x
Yield (DPS / Price) 0,68% 0,73%
Price to book (Price / BVPS) 4,76x 4,28x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 15,2% 16,7%
operating Leverage (Delta EBIT / Delta Sales) 2,82x 2,25x
Net Margin (Net Profit / Revenue) 10,8% 12,0%
ROA (Net Profit / Asset) 9,30% 10,6%
ROE (Net Profit / Equities) 15,0% 15,6%
Rate of Dividend 23,6% 20,3%
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   10,8% 9,73%
Cash Flow / Sales 15,4% 17,2%
Capital Intensity (Assets / Sales) 1,16x 1,13x
Financial Leverage (Net Debt / EBITDA) 0,07x 0,03x
Price Earning Ratio Help 
The blue ligne is the average P/E ratio (without estimates)
EPS & Dividend